In my role at Lecheng, I’ve transitioned from a distant observer of medical progress to an active participant in its most personal chapters. The moment a patient’s eyes light up upon hearing there’s a new, viable path forward is a profound privilege. This is the daily reality at Lecheng, where our unique “first-to-try” policy transforms global biomedical research into tangible clinical options. As of early 2026, this commitment has materialized into a robust portfolio of 19 approved cell and gene therapies, a collection I have watched grow from a hopeful concept into a concrete arsenal against some of the most challenging diseases.
The New Therapeutic Frontier: What Are Cell and Gene Therapies?
At its core, cell and gene therapy represents a fundamental shift from treating symptoms to addressing the root biological cause of disease. As one insightful article framed it, many diseases stem from a “fault” in our genetic “program”. These therapies act as “pioneering medical vanguards” that aim to repair or replace these faulty instructions, offering the potential to rewrite a patient’s health narrative. For example, they can engineer a patient’s own immune cells to become expert cancer hunters or introduce healthy genes to compensate for inherited disorders. The advantages are compelling: the potential for durable or even curative outcomes, reduced systemic side effects compared to conventional treatments like chemotherapy, and highly personalized therapeutic strategies.
The Lecheng Portfolio: 19 Approved Pathways to Treatment
| Technology Name | Treatment Target / Indication | Approximate Price (RMB) |
|---|---|---|
| Earlier Approved Technologies (Initial 15 Items) | ||
| Umbilical Cord Mesenchymal Stem Cell Injection for Knee Osteoarthritis | Knee Osteoarthritis | 36,000 per session |
| Airway Basal Stem Cell Therapy for Chronic Obstructive Pulmonary Disease (COPD) | COPD | 150,000 per session |
| Dental Pulp Mesenchymal Stem Cell Therapy for Periodontal Disease | Periodontal Disease (per tooth) | 59,800 per tooth |
| Airway Basal Stem Cell Therapy for Bronchiectasis | Bronchiectasis | 150,000 per session |
| Human Umbilical Cord Mesenchymal Stem Cells (VUM02 Injection) for Liver Cirrhosis | Liver Cirrhosis | 450,000 per course |
| Airway Basal Stem Cell Therapy for Interstitial Lung Disease | Interstitial Lung Disease | 150,000 per session |
| Umbilical Cord Mesenchymal Stem Cell Therapy for Premature Ovarian Insufficiency | Premature Ovarian Insufficiency | 80,000 per session |
| Gene Therapy for RPE65 Biallelic Mutation-Related Inherited Retinal Dystrophy | Genetic Retinal Disease (per eye) | 480,000 per eye |
| Human Umbilical Cord-Derived MSC Therapy for Heart Failure with Reduced Ejection Fraction | Heart Failure | 60,000 per session |
| Menstrual Blood-Derived MSC Therapy for Pulmonary Fibrosis | Pulmonary Fibrosis | 140,000 per course |
| Mesenchymal Stem Cell Therapy for Complications Post Bone Marrow Transplant | Post-Transplant Complications | 80,000 per vial |
| Personalized Dendritic Cell (DC) Vaccine for Malignant Tumors | Malignant Tumors | 150,000 per injection |
| Anti-EBV Infection Cell Vaccine Technology | EBV-related Diseases | 16,000 per session |
| Activated T-Lymphocyte Therapy for Preventing Postoperative Liver Cancer Recurrence | Prevention of Liver Cancer Recurrence | 100,000 per session |
| Human Umbilical Cord MSC Therapy for Rheumatoid Arthritis | Rheumatoid Arthritis | 50,000 per session |
| Newly Approved Technologies (Early 2026) | ||
| Autologous NK Cell Therapy Technology | Various cancers, immune regulation | ~30,000 – 50,000 per session (estimated market rate) |
| Human Umbilical Cord MSC Therapy for Type 2 Diabetes | Type 2 Diabetes (poorly controlled) | 58,000 per session (174,000 for a 3-session course) |
| KSD-101 Dendritic Cell (DC) Drug for EBV-related Hematologic Tumors | EBV-related Blood Cancers | Pricing upon consultation |
| German DC Immune Cell Therapy Technology | Various cancers | Pricing upon consultation |
Note: Prices are indicative and subject to change. Final treatment costs may vary based on individual patient assessment, specific treatment protocols, and hospital policies. Direct consultation with the respective hospitals in Lecheng is essential for accurate pricing and eligibility determination.
Navigating Access: The Lecheng Model
What makes this list possible is not just scientific innovation, but a pioneering policy framework. Lecheng operates as a regulated “medical gateway,” allowing for the controlled clinical use of overseas and domestic advanced therapies that are not yet widely available in China. This system ensures patient safety through rigorous expert review while dramatically shortening the wait time for life-changing treatments. For instance, the stem cell therapy for Type 2 Diabetes moved from approval to being a concrete, priced treatment option in a matter of weeks. My role is to help patients and medical professionals understand and navigate this unique ecosystem, transforming complex policy into personal opportunity.
Your Journey May Begin Here
This collection of 19 therapies is more than a catalog; it represents 19 different dialogues we can now have with patients who had previously heard “there are no more options.” If you or someone you care for is grappling with a condition mentioned here, I encourage you to look deeper. Explore the specifics, understand the eligibility criteria set by the hospitals like Ciming Boao International Hospital or Boao Super Hospital, and consider a professional consultation.
The path to treatment is a collaborative one. As a guide within the Lecheng system, I am available to help connect you with the relevant information and resources to evaluate if one of these pioneering paths is right for you. You can reach out for a preliminary discussion via the official Lecheng medical tourism service channels. Let’s explore the possibilities together.
